ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,385.14
0.08%
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs Yen
156.7275
0.02%
Brent Oil
79.395
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Zevra Therapeutics Inc (ZVRA)

  7. Zevra Therapeutics Inc (ZVRA) ニュース

ZVRA

Zevra Therapeutics (ZVRA)

Zevra Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ZVRA
日付受信時刻ニュースソース見出しコード企業名
2024/06/0506 : 13Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ZVRAZevra Therapeutics Inc
2024/06/0400 : 00GlobeNewswire Inc.Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
2024/05/1610 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
2024/05/1610 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
2024/05/1610 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
2024/05/1610 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
2024/05/1610 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
2024/05/1405 : 47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
2024/05/1005 : 34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVRAZevra Therapeutics Inc
2024/05/0920 : 30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor EventsNASDAQ:ZVRAZevra Therapeutics Inc
2024/05/0820 : 54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
2024/05/0820 : 00GlobeNewswire Inc.Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
2024/05/0120 : 30GlobeNewswire Inc.Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024NASDAQ:ZVRAZevra Therapeutics Inc
2024/04/2920 : 30GlobeNewswire Inc.Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024NASDAQ:ZVRAZevra Therapeutics Inc
2024/04/1606 : 01GlobeNewswire Inc.Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
2024/04/1020 : 30GlobeNewswire Inc.Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityNASDAQ:ZVRAZevra Therapeutics Inc
2024/03/2905 : 32GlobeNewswire Inc.Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
2024/03/2820 : 42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:ZVRAZevra Therapeutics Inc
2024/03/2705 : 30GlobeNewswire Inc.Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic HypersomniaNASDAQ:ZVRAZevra Therapeutics Inc
2024/03/2605 : 30GlobeNewswire Inc.Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ZVRAZevra Therapeutics Inc
2024/03/1820 : 30GlobeNewswire Inc.Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024NASDAQ:ZVRAZevra Therapeutics Inc
2024/03/0521 : 34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
2024/03/0422 : 24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
2024/03/0421 : 30GlobeNewswire Inc.Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
2024/02/2821 : 30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:ZVRAZevra Therapeutics Inc
2024/02/1506 : 51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ZVRAZevra Therapeutics Inc
2024/02/0621 : 30GlobeNewswire Inc.Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ZVRAZevra Therapeutics Inc
2024/02/0311 : 22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
2024/02/0310 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
2024/02/0310 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVRA

最近閲覧した銘柄

NYSE
CVX
Chevron
NYSE
XOM
Exxon Mobil
FX
USDGBP
US Dollar vs Sterling
AMEX
XLF
Financial Select Sector
CCOM
US500
US 500
FX
USDEUR
US Dollar vs Euro
CCOM
SILVER
SILVER
USOTC
RHHBY
Roche (QX)
SPI
SP500
S&P 500
NYSE
MRK
Merck
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
NKE
Nike
USOTC
BASFY
BASF (QX)
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有